Pharma

The Readout Meghana Keshavan

STAT Plus: Four health care and biotech updates to stay on top of this week

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Express Scripts overcharging postal workers, Gilead’s AIDS drug price, and more

Pharmalot Ed Silverman

STAT Plus: European Commission reaches deal with Vifor for ‘disparaging’ its only rival in iron deficiency market

Pharmalot Bob Herman and Ed Silverman

STAT Plus: Express Scripts overcharged postal workers by $45 million, audit says

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA rare disease innovation hub, fewer U.S. drug shortages, and more

The Readout Meghana Keshavan

STAT Plus: Novo, Lilly shares sink due to concerns over competition

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Here come Medicare’s first negotiated drug prices

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Novartis not ready to admit a $3 billion mistake

The Readout Elaine Chen

STAT Plus: The biotech news stories you need to know today

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more

Pharma Andrew Joseph

STAT Plus: Novartis hedges on when it might submit myelofibrosis drug for approval

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more

The Readout Elaine Chen

STAT Plus: It’s happy hour (for now) for Alnylam

Pharma Andrew Joseph

STAT Plus: A second Roche obesity drug shows promise in early studies

Pharmalot Ed Silverman and Rachel Cohrs Zhang

STAT Plus: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down

Politics Annalisa Merelli

STAT Plus: Sen. Menendez’s conviction may cost pharma a key ally in Congress

The Readout Elaine Chen

STAT Plus: Roche looks to have a competitive GLP-1 drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Vertex suing HHS over a fertility program, Hawaii losing a PBM suit, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Senate aides meeting with Novo Nordisk, private drug prices in Germany, and more

The Readout Meghana Keshavan

STAT Plus: What are the odds we get an heir to Paxlovid?

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more

The Readout Meghana Keshavan

STAT Plus: Element Biosciences raises another massive round

The Readout Elaine Chen

STAT Plus: Can you get satiety with GLP-1s without the nausea?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more

Pharma Matthew Herper and Elaine Chen

STAT Plus: Pfizer says it will advance once-daily GLP-1 pill after all

Pharmalot Ed Silverman

STAT Plus: FTC plans to sue PBMs over the high cost of insulin and other medicines

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about biopharma layoffs, Purdue bankruptcy talks, and more